Brad Ginesin manages Polar Capital LP, a long/short hedge fund he founded in 2000. He’s worked on and managed several equity trading desks including Monarch Financial and WFP Management. He has been a regular contributor to Real Money since 2021, specializing in market sector coverage.
Ginesin graduated from Cornell University in 1992 with a degree in Applied Econ & Business Mgmt. He is a value investor who follows fundamental analysis. He avoids momentum stocks and hype favoring a long-term investing strategy.
Ginesin is the author of The Trading Desk, a Wall Street inspired novel published in 2021. In addition to being a long-term investor, he is also a long distance runner who is currently training for his fifth marathon.
Recent Articles By The Author
Applied Materials is a technology play that offers both the right price and the right equipment for investors looking for an AI edge.
RIVN has fallen by more than 80% since it went public in 2021, but now the risk might just be in investors' favor.
Let's look at why holding this kind of stock could mean losses for greedy investors.
Here's why a myopic view from Wall Street could fail to see this American automaker's steady progress as it carries investors to a brighter 2023.
The stock is already down about 15% in 2023 as the pharmaceutical giant gets set to report earnings.
Here I'll tackle these cultish stocks in the voice of my favorite columnist -- and let you know how I think they should be handled.
Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
At least one thing is clear from my 'report card' for 2022 -- it's easier to find dogs in a bear market than long ideas.